• Manqoosh
• January 18, 2022
• Uncategorized
• 0 Comments

According to analysts, Sarepta Therapeutics’s stock has a predicted upside of 36.80% based on their 12-month price targets. What’s even more important is that Sarepta is demonstrating its ability to develop novel therapies for difficult-to-treat diseases. And its pipeline features other candidates that target this disease. Sarepta Therapeutics may not yet be profitable, but the company looks like a rising …